Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme of the metabolic pathway that produces cholesterol and other isoprenoids.

In this paper, researchers investigated the molecular changes associated with pravastatin treatment compared with placebo administration by metabolic profiling 231 lipoprotein and metabolite measures in the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial) study. Results demonstrate the widespread effects of pravastatin treatment on lipoprotein subclass profiles and fatty acids.